Crizotinib in ROS1-rearranged non-small | 合法藥品大搜索

由 AT Shaw 著作 · 2019 · 被引用 149 次 — After a median follow-up of 62.6 months, median overall survival in patients with ROS1-rearranged advanced NSCLC receiving crizotinib was ... Read More

由 K Masuda 著作 · 2019 · 被引用 7 次 — Crizotinib, a small-molecule TKI, has been demonstrated to be an efficacious drug against c-ros oncogene 1-rearranged NSCLC (ROS1-NSCLC) ... Read More

由 DG Bebb 著作 · 2019 · 被引用 3 次 — As the sole approved treatment for ROS1-rearranged nsclc, crizotinib has been demonstrated, through a variety of clinical trials and retrospective ... Read More

由 AT Shaw 著作 · 2019 · 被引用 149 次 — Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. Read More

2014年11月20日 — In this study, crizotinib showed marked antitumor activity in patients with advanced ROS1-rearranged NSCLC. ROS1 rearrangement defines a ... Read More

修訂後給付規定. 原給付規定. 9.50. Crizotinib (如Xalkori)：(104/9/1、106/11/1、​107/5/1、108/7/1、108/9/1)： 1.適用於ALK陽性之晚期非小細胞肺癌患者。 Read More

由 AT Shaw 著作 · 2014 · 被引用 1533 次 — The ROS1 oncogene encodes an orphan receptor tyrosine kinase related to anaplastic lymphoma kinase (ALK), along with members of the ... Read More

由 AT Shaw 著作 · 2014 · 被引用 1533 次 — Introduction. The ROS1 oncogene encodes an orphan receptor tyrosine kinase related to anaplastic lymphoma kinase (ALK), along with ... Read More

由 AT Shaw 著作 · 2019 · 被引用 149 次 — Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001. A.T. Shaw. Read More